系统性硬化症患者肺炎球菌疫苗接种的免疫原性与安全性
44例系统性硬化症(SSc)患者和49名对照接种PCV13或PPV23,其中12例患者使用改善病情抗风湿药(DMARDs)。未用DMARDs的SSc患者和对照组接种后两种血清型抗体均显著升高(P<0.001),用DMARDs者仅6B型升高(P=0.041);PCV13与PPV23免疫原性无显著差异。
要点
- 未用DMARDs的SSc患者接种肺炎球菌疫苗后抗体应答满意。
- 使用合成DMARDs的SSc患者接种后抗体水平较低。
- PCV13与PPV23的免疫原性无显著差异。
核心结论
- 未接受DMARDs治疗的SSc患者接种PCV13或PPV23均可产生满意的抗体应答,而接受合成DMARDs治疗的患者应答较低。
- 肺炎球菌疫苗类型(结合疫苗或多糖疫苗)对SSc患者抗体应答无显著影响。
研究设计与样本
- 研究纳入44例SSc患者和49名对照,各接受一剂PCV13或PPV23。
- 12例SSc患者正在使用DMARDs治疗。
- 采用ELISA法检测疫苗接种前及接种后4-6周针对肺炎球菌多糖6B和23F的抗体水平,并用调理吞噬试验研究23F血清型的抗体功能。
主要发现
- 未用DMARDs的SSc患者和对照组接种后两种血清型抗体水平均显著升高(P<0.001),使用DMARDs的SSc患者仅6B型显著升高(P=0.041)。
- 与其他组相比,接受DMARDs的SSc患者接种后两种血清型抗体水平均较低。
- 三组调理吞噬试验结果均显著升高。
- PCV13与PPV23之间免疫原性未见显著差异。
关键数值与推荐
- 接种时各组人数、女性比例和平均年龄:未用DMARDs的SSc患者32例、94%、57.5岁;使用DMARDs的SSc患者12例、100%、55.5岁;对照组49名、63%、50.6岁。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To study the impact of disease and treatment with DMARDs on antibody response elicited by either pneumococcal conjugate vaccine (PCV13) or pneumococcal polysaccharide vaccine (PPV23) in patients with SSc. METHODS: Forty-four SSc patients and 49 controls received a dose of either PCV13 or PPV23. Twelve patients were treated with DMARDs. Antibody levels to pneumococcal polysaccharides 6B and 23 F were measured before and 4-6 weeks after vaccination using ELISA. Antibody functionality was studied using opsonophagocytic assay performed on serotype 23 F. RESULTS: Number of patients, percentage female and mean age (years) at vaccination were: 32, 94%, 57.5 years in SSc without DMARDs; 12, 100%, 55.5 years in SSc on DMARDs and 49, 63% and 50.6 years in controls. Post-vaccination antibody levels for both serotypes increased significantly in SSc without DMARDs and controls (P < 0.001), but in SSc on DMARDs only for 6B (P = 0.041). Compared with the other groups, patients with SSc receiving DMARDs had lower post-vaccination antibody levels for both serotypes. Opsonophagocytic assay increased significantly in all three groups. No significant difference in immunogenicity between PCV13 and PPV23 was seen. CONCLUSION: Pneumococcal vaccination using either PCV13 or PPV23 yielded satisfactory antibody response in SSc patients without DMARD treatment, but a lower response in patients treated with synthetic DMARDs. Type of pneumococcal vaccine (conjugate or polysaccharide) did not significantly influence antibody response. TRIAL REGISTRATION: ClinicalTrials.gov, http://clinicaltrials.gov, NCT02240888.
引用
- Hesselstrand R, Nagel J, Saxne T, et al. Immunogenicity and safety of pneumococcal vaccination in patients with systemic sclerosis. Rheumatology (Oxford). 2018. PMID: 29325173. doi:10.1093/rheumatology/kex471
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。